Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Vaccine

• Publication date

  2007-01-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2006.07.053PMID 16949181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village.

  2005cited by this paper
• The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium falciparum Strain FVO Expressed in Escherichia coli Protects Aotus nancymai against Challenge with Homologous Erythrocytic-Stage Parasites

  2005cited by this paper
• Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia

  2004cited by this paper
• Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

  2004cited by this paper
• Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli.

  2004cited by this paper
• Analysis of Immunological Nonresponsiveness to the 19-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium yoelii: Rescue by Chemical Conjugation to Diphtheria Toxoid (DT) and Enhancement of Immunogenicity by Prior DT Vaccination

  2003cited by this paper
• Identification of T Cell Epitopes on the 33-kDa Fragment of Plasmodium yoelii Merozoite Surface Protein 1 and Their Antibody-Independent Protective Role in Immunity to Blood Stage Malaria1

  2002cited by this paper
• Nature and Specificity of the Required Protective Immune Response That Develops Postchallenge in Mice Vaccinated with the 19-Kilodalton Fragment of Plasmodium yoelii Merozoite Surface Protein 1

  2002cited by this paper
• In Vivo Expression and Immunological Studies of the 42-Kilodalton Carboxyl-Terminal Processing Fragment of Plasmodium falciparum Merozoite Surface Protein 1 in the Baculovirus-Silkworm System

  2002cited by this paper
• Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge.

  2002cited by this paper
• Protective Immune Responses to the 42-Kilodalton (kDa) Region of Plasmodium yoelii Merozoite Surface Protein 1 Are Induced by the C-Terminal 19-kDa Region but Not by the Adjacent 33-kDa Region

  2002cited by this paper
• Efficacy of Two Alternate Vaccines Based on Plasmodium falciparum Merozoite Surface Protein 1 in anAotus Challenge Trial

  2001cited by this paper
• A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

  2001cited by this paper
• Immunoglobulin G3 Antibodies Specific for the 19-Kilodalton Carboxyl-Terminal Fragment of Plasmodium yoelii Merozoite Surface Protein 1 Transfer Protection to Mice Deficient in Fc-γRI Receptors

  2000cited by this paper
• Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli.

  2000cited by this paper
• Human antibodies to the 19 kDa C‐terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

  1999cited by this paper
• A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia.

  1998cited by this paper
• Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria

  1998cited by this paper
• Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effect

  1997cited by this paper
• Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

  1996cited by this paper
• A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria

  1996cited by this paper
• Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection

  1996cited by this paper
• Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1.

  1995cited by this paper
• Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys

  1995cited by this paper
• Malaria parasites and erythrocyte invasion.

  1994cited by this paper
• Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.

  1994cited by this paper
• Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

  1994cited by this paper
• Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus

  1993cited by this paper
• Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

  1993cited by this paper
• A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth.

  1992cited by this paper
• Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum

  1992cited by this paper
• A malaria merozoite surface protein (MSP1)-structure, processing and function.

  1992cited by this paper
• Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion.

  1991cited by this paper
• Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

  1991cited by this paper
• Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195

  1991cited by this paper
• A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies

  1990cited by this paper
• Precursor to the major merozoite surface antigen of Plasmodium yoelii: cloning and sequencing of the middle 1.9-kb region.

  1989cited by this paper
• A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii.

  1989cited by this paper
• The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody.

  1988cited by this paper
• Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum.

  1987cited by this paper
• Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria.

  1987cited by this paper
• Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro.

  1987cited by this paper
• Synchronization of Plasmodium falciparum erythrocytic stages in culture.

  1979cited by this paper

• Korea vaccinia viral vectored vaccine expressing 33 kDa fragment of Plasmodium vivax merozoite surface protein 1 elicited strong humoral immune responses in mice

  2021cites this paper
• Antibody Profile Comparison against MSP1 Antigens of Multiple Plasmodium Species in Human Serum Samples from Two Different Brazilian Populations Using a Multiplex Serological Assay

  2021cites this paper
• Mechanisms of Stage-Transcending Protection Following Immunization of Mice with Late Liver Stage-Arresting Genetically Attenuated Malaria Parasites

  2015cites this paper
• A Chimeric Plasmodium falciparum Merozoite Surface Protein Vaccine Induces High Titers of Parasite Growth Inhibitory Antibodies

  2013cites this paper
• T Cell Epitope Regions of the P. falciparum MSP1-33 Critically Influence Immune Responses and In Vitro Efficacy of MSP1-42 Vaccines

  2011influential citation
• Enhancing the efficacy of viral vector blood-stage malaria vaccines

  2011cites this paper
• Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.

  2011cites this paper
• Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

  2010cites this paper
• Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4

  2010cites this paper
• Studies on Immunology of Leishmania Mexicana

  2010cites this paper
• Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment.

  2009cites this paper
• Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria

  2009cites this paper
• Isolation and expression of UB05, a Plasmodium falciparum antigen recognised by antibodies from semi-immune adults in a high transmission endemic area of the Cameroonian rainforest

  2009cites this paper
• Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacy against Plasmodium chabaudi malaria based on prechallenge antibody responses Running title: Correlates of AMA1 and MSP1 vaccine-induced immunity

  2008cites this paper
• Prediction of Merozoite Surface Protein 1 and Apical Membrane Antigen 1 Vaccine Efficacies against Plasmodium chabaudi Malaria Based on Prechallenge Antibody Responses

  2008cites this paper
• Fine Specificity of Neonatal Lymphocytes to an Abundant Malaria Blood-Stage Antigen: Epitope Mapping of Plasmodium falciparum MSP1331

  2008cites this paper
• Malaria vaccines: are we getting closer?

  2007cites this paper